Clinical trial NCT03512301: CAMCI: Advancing the Use of Computerized Screening in Healthcare
Official title: CAMCI: Advancing the Use of Computerized Screening in Healthcare
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognitive Dysfunction
Cognitive Impairment
Cognitive Decline
Cognitive Change
Lead sponsor: Psychology Software Tools, Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Aging (NIA)
First posted: 2018-04-30
Enrollment: 773
Sex: ALL
Minimum age (years): 60
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: Cognitive impairment is a significant health problem in the United States, resulting in costs over $100 billion a year. We will provide an efficient, effective, and financially intelligent solution to Primary Care Physician's to identify cognitive impairment in the earliest stages, delay progression through appropriate treatment, and to afford patients the opportunity to make future plans at a time when symptoms are mild and patients are able to make informed decisions concerning financial and life activities. This has the potential to delay devastating effects of cognitive impairment, and to lessen the financial burden on the health care system in the United States.

Detailed description: Cognitive dysfunction in the elderly population, ranging from simple forgetfulness to a diagnosis of Alzheimer's disease, can impact one's quality of life and ability to function in daily activities. It is crucial that decline be detected as early as possible in order to evaluate whether the cause is treatable, and to employ appropriate treatment, if applicable. The majority of older patients rely on their primary care physician for the bulk of their healthcare needs, but there is a lack of sensitive tools available, and there is a lack of physician's time to use the tools, leading to a failure to provide therapeutic intervention at the earliest stages of loss to potentially slow the progression of disease. Psychology Software Tools, Inc. (PST) has developed the Computer Assessment of Memory and Cognitive Impairment (CAMCI), a computerized screening tool for detection of early signs of cognitive decline, which has been shown to be more effective in the identification of patients with subtle cognitive loss than the tools most frequently used within the primary care physician (PCP) office. CAMCI would provide an option for PCPs and clinicians to provide therapeutic intervention prior to a diagnosis of dementia. Recent additions to Current Procedural Terminology (CPT) codes permit insurance reimbursement for neuropsychological testing by a computer, including time for the physician's or clinical psychologist's interpretation and reporting. The introduction of this new revenue stream for PCPs and clinicians, coupled with the characteristics of being brief and self-administered make CAMCI an attractive option for improving early intervention, providing an intelligent business solution for healthcare professionals, and a useful and effective tool that allows physicians to better evaluate and serve their patients. The specific aims included in the current project focus on activities required to successfully move CAMCI to commercialization by extending support for late stage research and product development, including regulatory strategy and intellectual property development, data collection to replicate key studies, product extension through increasing minority representation, and development of a measure of meaningful change. The ultimate goal is to streamline commercialization of CAMCI, and to provide a useful and effective tool in the detection of cognitive dysfunction to physicians, the providers of the majority of healthcare to the elderly population, to improve efficiency and effectiveness of clinical practice.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent
* Adequate visual and auditory acuity to allow neuropsychological testing
* Able to read, write and understand study and test requirements
* Within the age range of 60+

Exclusion Criteria:

* Significant neurologic disease, such as multi-infarct dementia, Parkinson's disease, epilepsy, stroke, multiple sclerosis or head trauma
* History of major depression or other major psychiatric disorder, such as, schizophrenia and bipolar disorder
* History of consuming 5 or more alcoholic drinks per day on a regular basis
* MoCA score \<10

Primary outcomes:
measure: Agreement to reference standard
timeFrame: baseline
measure: Agreement to non-reference standard
timeFrame: baseline
Secondary outcomes:
measure: Criterion validity correlation analysis
timeFrame: baseline
measure: Test/retest reliability
timeFrame: 2-3 weeks
Other outcomes:
measure: Measure of significant change
timeFrame: baseline, 6 months, 12 months, 24 months post baseline
Locations:
city: Indianapolis
country: United States
facility: Indiana University
state: Indiana
city: Sharpsburg
country: United States
facility: Psychology Software Tools
state: Pennsylvania
city: Houston
country: United States
facility: Baylor College of Medicine
state: Texas
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
affiliation: Psychology Software Tools
name: Anthony Zuccolotto
role: STUDY_DIRECTOR
References: